BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34953676)

  • 1. NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort.
    Heynemann S; Yu H; Churilov L; Rivalland G; Asadi K; Mosher R; Hirsch F; Rivard C; Mitchell P
    Clin Lung Cancer; 2022 Mar; 23(2):e90-e98. PubMed ID: 34953676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers.
    Lin K; Rubinfeld B; Zhang C; Firestein R; Harstad E; Roth L; Tsai SP; Schutten M; Xu K; Hristopoulos M; Polakis P
    Clin Cancer Res; 2015 Nov; 21(22):5139-50. PubMed ID: 26156394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b.
    Levan K; Mehryar M; Mateoiu C; Albertsson P; Bäck T; Sundfeldt K
    BMC Cancer; 2017 May; 17(1):303. PubMed ID: 28464843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico analysis and immunohistochemical characterization of NaPi2b protein expression in ovarian carcinoma with monoclonal antibody Mx35.
    Soares IC; Simões K; de Souza JE; Okamoto OK; Wakamatsu A; Tuma M; Ritter G; Alves VA
    Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):165-72. PubMed ID: 22553815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
    Gerber DE; Infante JR; Gordon MS; Goldberg SB; Martín M; Felip E; Martinez Garcia M; Schiller JH; Spigel DR; Cordova J; Westcott V; Wang Y; Shames DS; Choi Y; Kahn R; Dere RC; Samineni D; Xu J; Lin K; Wood K; Royer-Joo S; Lemahieu V; Schuth E; Vaze A; Maslyar D; Humke EW; Burris HA
    Clin Cancer Res; 2020 Jan; 26(2):364-372. PubMed ID: 31540980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular genetic alterations in thyroid transcription factor 1-negative lung adenocarcinoma in cytology specimens: A subset with aggressive behavior and a poor prognosis.
    Rodriguez EF; VandenBussche CJ; Chowsilpa S; Maleki Z
    Cancer Cytopathol; 2018 Oct; 126(10):853-859. PubMed ID: 30199148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis of NaPi2b protein (MX35 antigen) expression and subcellular localization in human normal and cancer tissues.
    Kiyamova R; Shyian M; Lyzogubov VV; Usenko VS; Gout T; Filonenko V
    Exp Oncol; 2011 Sep; 33(3):157-61. PubMed ID: 21956469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation.
    Cho MS; Park CH; Lee S; Park HS
    PLoS One; 2020; 15(3):e0230622. PubMed ID: 32196518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
    Cheng H; Janakiram M; Borczuk A; Lin J; Qiu W; Liu H; Chinai JM; Halmos B; Perez-Soler R; Zang X
    Clin Cancer Res; 2017 Feb; 23(3):825-832. PubMed ID: 27553831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
    Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
    Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.
    Yu H; Brustugun OT; Ekman S; Botling J; La Fleur L; Micke P; Solberg S; Berglund A; Rivard C; Hirsch FR
    Clin Lung Cancer; 2021 Jul; 22(4):e555-e562. PubMed ID: 33214079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
    Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
    Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between molecular analysis, diagnosis according to the 2015 WHO classification of unresected lung tumours and TTF1 expression in small biopsies and cytology specimens from 344 non-small cell lung carcinoma patients.
    Russell PA; Rogers TM; Solomon B; Alam N; Barnett SA; Rathi V; Williams RA; Wright GM; Conron M
    Pathology; 2017 Oct; 49(6):604-610. PubMed ID: 28811082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer.
    Lui NS; Yang YW; van Zante A; Buchanan P; Jablons DM; Lemjabbar-Alaoui H
    PLoS One; 2016; 11(2):e0148911. PubMed ID: 26882224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma.
    Xu HJ; Quinlan DC; Davidson AG; Hu SX; Summers CL; Li J; Benedict WF
    J Natl Cancer Inst; 1994 May; 86(9):695-9. PubMed ID: 8158700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool.
    Mandarano M; Bellezza G; Belladonna ML; Vannucci J; Gili A; Ferri I; Lupi C; Ludovini V; Falabella G; Metro G; Mondanelli G; Chiari R; Cagini L; Stracci F; Roila F; Puma F; Volpi C; Sidoni A
    Front Immunol; 2020; 11():839. PubMed ID: 32536910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of Bcl-2 gene expression and its prognostic value in non-small cell lung cancer.
    Yilmaz A; Savaş I; Dizbay Sak S; Güngör A; Kaya A; Serinsöz E; Savaş B
    Tuberk Toraks; 2005; 53(4):323-9. PubMed ID: 16456730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical Analysis of Primary Pulmonary Lymphoepithelioma-like Carcinoma in 8 Patients].
    Zhao H; Chen J
    Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):168-175. PubMed ID: 32209185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic significance of HER2 overexpression in non-small cell lung cancer.
    Takenaka M; Hanagiri T; Shinohara S; Kuwata T; Chikaishi Y; Oka S; Shigematsu Y; Nagata Y; Shimokawa H; Nakagawa M; Uramoto H; So T; Tanaka F
    Anticancer Res; 2011 Dec; 31(12):4631-6. PubMed ID: 22199341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of monoclonal antibodies specific for the human sodium-dependent phosphate co-transporter NaPi2b.
    Kiyamova R; Gryshkova V; Ovcharenko G; Lituyev D; Malyuchik S; Usenko V; Khozhayenko Y; Gurtovyy V; Yin B; Ritter G; Old L; Filonenko V; Gout I
    Hybridoma (Larchmt); 2008 Aug; 27(4):277-84. PubMed ID: 18724815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.